E2 ModeratePreliminaryPEM unclearMechanisticPeer-reviewedReviewed
Single nucleotide polymorphisms and genotypes of transient receptor potential ion channel and acetylcholine receptor genes from isolated B lymphocytes in myalgic encephalomyelitis/chronic fatigue syndrome patients.
Marshall-Gradisnik, Sonya, Johnston, Samantha, Chacko, Anu et al. · The Journal of international medical research · 2016 · DOI
Quick Summary
This small study looked at genetic differences in immune cells (B cells) from ME/CFS patients compared to healthy people. Researchers found that ME/CFS patients had more variations in genes controlling calcium flow and acetylcholine signaling—two processes important for immune cell communication. Some of these genetic variations were much more common in patients with ME/CFS, suggesting they might play a role in the disease.
Why It Matters
This research provides genetic evidence supporting a potential immune mechanism in ME/CFS, particularly linking B cell dysfunction to calcium and acetylcholine signaling abnormalities. The findings are relevant to recent clinical observations that some ME/CFS patients respond to anti-CD20 antibody therapy and show muscarinic antibody positivity, suggesting these genetic variants may help identify subgroups of patients who might benefit from targeted treatments.
Observed Findings
- 78 SNPs identified in acetylcholine receptor genes in ME/CFS patients, with 35 concentrated in the muscarinic M3 receptor gene.
- 9 specific genotypes found with significantly elevated odds ratios (7.11–26.67) in ME/CFS patients compared to controls.
- Genetic variations identified in both TRP ion channel genes (TRPV2, TRPM3, TRPM4, TRPC6) and nicotinic/muscarinic acetylcholine receptor genes.
- Variations located primarily in introns and 3' untranslated regions, suggesting potential regulatory rather than protein-coding impacts.
Inferred Conclusions
- Genetic polymorphisms in calcium-regulating ion channels and acetylcholine receptors may contribute to altered B cell function in ME/CFS.
- Calcium dysregulation and acetylcholine receptor signaling dysfunction may be central mechanisms in ME/CFS pathogenesis.
- These genetic variations could help stratify ME/CFS patients and identify those most likely to respond to B cell-targeted immunotherapies.
Remaining Questions
- Do these genetic variants functionally impair calcium signaling or acetylcholine receptor expression in ME/CFS B cells?
- Can these genetic findings predict which ME/CFS patients will respond to anti-CD20 therapy or have muscarinic antibodies?
What This Study Does Not Prove
This study does not prove that these genetic variations cause ME/CFS—it only shows association in a very small sample. The study cannot establish whether these genetic differences directly cause the observed immune dysfunction or are secondary consequences of the disease. Additionally, genetic variation does not necessarily translate to functional abnormality without further cellular and biochemical validation.
Tags
Symptom:Fatigue
Biomarker:Gene ExpressionBlood BiomarkerAutoantibodies
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1177/0300060516671622
- PMID
- 27834303
- Review status
- Editor reviewed
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.